Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.61 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696700 | 0.85 | SYK (0.52) | SYKGPR119JAK2JAK1POLB | |
| SCHEMBL13858221 | 0.84 | POLB (0.47) | SYKGPR119JAK2JAK1STS | |
| SCHEMBL3820292 | 0.83 | SYK (0.44) | SYKOPRD1OPRK1TRPV3 | |
| SCHEMBL25389281 | 0.81 | SYK (0.50) | SYKTACR1MAPTGPR119HRH3 | |
| SCHEMBL30327670 | 0.80 | FFAR4 (0.59) | SYKTACR1MAPTGPR119HRH3 | |
| SCHEMBL1181843 | 0.80 | GPR119 (0.54) | SYKGPR119JAK2JAK1POLB | |
| SCHEMBL20754002 | 0.80 | JAK2 (0.48) | SYKTACR1MAPTGPR119JAK2 | |
| SCHEMBL22328947 | 0.80 | CCR2 (0.42) | SYKHRH3TRPV3 | |
| SCHEMBL26081094 | 0.79 | SYK (0.48) | SYKTACR1MAPTGPR119JAK2 | |
| SCHEMBL25163987 | 0.79 | HSD17B10 (0.53) | SYKTACR1MAPTGPR119HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | disclosed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-1763347-A4 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7449467-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | PFIZER INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449467-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | PFIZER INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449467-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | PFIZER INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1763351-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1763347-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-26 | — | — | US | disclosed |
| WO-2006004741-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004684-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | SYK 3510/4885TACR1 1512/4885MAPT 1598/4885 |
| US-20200253967-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | SYK 3510/4885TACR1 1512/4885MAPT 1598/4885 |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | SYK 3720/4885TACR1 71/4885MAPT 4744/4885 |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | SYK 3720/4885TACR1 71/4885MAPT 4744/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | SYK 3028/4885TACR1 871/4885MAPT 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.